Avid Bioservices Inc (CDMO)

[entdoc]

senrex thanks. I enjoy what chartists write. Two-dimensional, or two-axis, information is probably mostly what professional investors program into their "buy" paradigm, and PPHM is now undeniably a buy. PPHM performance last year was quite good despite fincial and credit market meltdowns. Good Bavi numbers popped up in clinical trials reports last year. And Cotara is still an item. PPHM ally with its anti-TNT platform is none other than China, and that includes china's health AND military departments. If PPHM's clinical candidates had produced less promising numbers, the present support pattern would not have held. And CJ wrote here that more study data on Bavi is forthcoming, and The numbers must be exciting. Doubters be warned:a spectacular set of numbers from any PII trial will shine the light right on our baby, and there are big leaguers in house now who are watching all this very closely and will be able to vouch for the results. Did FDA or Uncle have a hand in putting the new pros in the lineup? Will new government policies help move worthy product down the endless pipeline to treatment tables?